Olympus Corporation (OLYMY)
OTCMKTS · Delayed Price · Currency is USD
13.40
+0.40 (3.08%)
Oct 6, 2025, 9:30 AM EDT
Olympus Revenue
Olympus had revenue of 206.51B JPY in the quarter ending June 30, 2025, a decrease of -12.06%. This brings the company's revenue in the last twelve months to 969.02B, up 0.31% year-over-year. In the fiscal year ending March 31, 2025, Olympus had annual revenue of 997.33B with 6.53% growth.
Revenue (ttm)
969.02B JPY
Revenue Growth
+0.31%
P/S Ratio
2.11
Revenue / Employee
33.08M JPY
Employees
29,297
Market Cap
14.15B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 997.33B | 61.12B | 6.53% |
Mar 31, 2024 | 936.21B | 54.29B | 6.16% |
Mar 31, 2023 | 881.92B | 13.06B | 1.50% |
Mar 31, 2022 | 868.87B | 138.32B | 18.93% |
Mar 31, 2021 | 730.54B | -66.87B | -8.39% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Elite Pharmaceuticals | 105.45M |
Glass House Brands | 221.55M |
Northwest Biotherapeutics | 1.09M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
Jushi Holdings | 256.36M |
Nuo Therapeutics | 1.95M |